Fennec Pharmaceuticals (TSE:FRX) Reaches New 52-Week High - What's Next?

Fennec Pharmaceuticals Inc. (TSE:FRX - Get Free Report) shares reached a new 52-week high during trading on Friday . The company traded as high as C$12.15 and last traded at C$12.14, with a volume of 809 shares changing hands. The stock had previously closed at C$11.89.

Fennec Pharmaceuticals Stock Down 4.4%

The stock has a market capitalization of C$224.09 million, a price-to-earnings ratio of -196.84 and a beta of 0.25. The business has a fifty day moving average of C$10.46 and a 200 day moving average of C$9.36. The company has a debt-to-equity ratio of -620.83, a current ratio of 7.80 and a quick ratio of 10.17.

Insider Activity at Fennec Pharmaceuticals

In other Fennec Pharmaceuticals news, Director Rostislav Christov Raykov sold 16,667 shares of the business's stock in a transaction that occurred on Friday, May 16th. The stock was sold at an average price of C$9.49, for a total value of C$158,203.16. Also, Senior Officer Robert Christopher Andrade bought 8,220 shares of the business's stock in a transaction on Monday, June 2nd. The stock was purchased at an average cost of C$6.99 per share, for a total transaction of C$57,433.14. Over the last three months, insiders have sold 38,076 shares of company stock worth $391,650. Insiders own 16.20% of the company's stock.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.